^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

DF9001

i
Other names: DF9001
Associations
Company:
Dragonfly Therap
Drug class:
EGFR inhibitor, NK cell stimulant
Related drugs:
Associations
6ms
Study of DF9001 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=242, Recruiting, Dragonfly Therapeutics | N=362 --> 242 | Trial completion date: Dec 2026 --> Nov 2027 | Trial primary completion date: Oct 2024 --> Aug 2025
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
RET mutation • RAS wild-type
|
Keytruda (pembrolizumab) • DF9001
9ms
Study of DF9001 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=362, Recruiting, Dragonfly Therapeutics | Trial primary completion date: Oct 2023 --> Oct 2024
Trial primary completion date • Combination therapy • Metastases
|
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
RET mutation • RAS wild-type
|
Opdivo (nivolumab) • DF9001
over1year
Study of DF9001 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=362, Recruiting, Dragonfly Therapeutics | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy • Metastases
|
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
RET mutation • RAS wild-type
|
Opdivo (nivolumab) • DF9001
2years
Study of DF9001 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=362, Not yet recruiting, Dragonfly Therapeutics
New P1/2 trial • Combination therapy • Metastases
|
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
RET mutation • RAS wild-type
|
Opdivo (nivolumab) • DF9001